Fibrinogen Early In Severe Trauma StudY II

Обзор

Annually over 7000 Australians are treated for severe trauma. Haemorrhage secondary to severe trauma is a major cause of potentially preventable death and poor outcomes in Australian adults. Severe trauma may trigger changes in blood clotting mechanisms and factor levels leading to inhibition of clot formation and reduced clot strength. This results in the inability of the severely injured trauma patient to form adequate clots to help stop bleeding. There is good evidence to suggest the loss of clotting factors during haemorrhage is associated with worse outcomes and it is thought the early replacement of these factors may reduce bleeding and improve patient outcomes. Fibrinogen is a key clotting factor that helps bind clots together and early fibrinogen replacement may improve outcomes. Currently fibrinogen is replaced using cryoprecipitate, a blood product made from blood donated by healthy donors which is a precious resource. It can take a significant amount of time to administer as it is frozen and stored in the blood bank. Timely administration of cryoprecipitate is difficult as it requires thawing prior to transfusion. The large doses of cryoprecipitate used in traumatic haemorrhage can put strain on local blood banks in supplying requested units in a timely manner. Additionally, the widely dispersed population of Australia introduces logistic challenges to the maintenance of adequate cryoprecipitate stocks to individual hospital blood banks, especially in remote regions. However, cryoprecipitate contains a number of other coagulation factors (not just fibrinogen) that may be instrumental in clot formation and resistance to fibrinolysis. Fibrinogen concentrate is an alternative product used to assist in blood clotting. It is a dry powder form of fibrinogen and can be reconstituted at the bedside and given quickly. The use of a fibrinogen factor concentrate with a long shelf life that is easy to use has significant implications for both large urban metropolitan areas and remote isolated communities. The timing and mode of fibrinogen replacement in traumatic haemorrhage has implications for patient outcomes, blood product availability, costs and the national blood supply. Despite the importance of fibrinogen replacement in traumatic haemorrhage, there have been no clinical trials powered for clinical outcomes directly comparing fibrinogen concentrate and cryoprecipitate. FEISTY II will evaluate the efficacy, safety and cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate in trauma patients with major haemorrhage. FEISTY II is a phase III randomised trial which will enrol 850 patients from Australian and New Zealand major trauma centres, with a primary patient outcome of days alive out of hospital at day 90 after injury. Severely injured trauma patients who require blood transfusion and have evidence of low fibrinogen levels will be randomised to receive either fibrinogen concentrate or standard care with cryoprecipitate

Вмешательства

• Препарат Fibrinogen Concentrate
  3g Fibrinogen Concentrate
• Другое Cryoprecipitate
  10U WB or 4U Apheresis Cryoprecipitate

Первичные конечные точки

• Days Alive and Out of Hospital at 90 Days [Срок оценки: 90 Days]

Вторичные конечные точки (10)

• Number RBC Units at 24 hours [Срок оценки: 24 hours]
• All cause mortality at 90 days [Срок оценки: 90 days]
• All cause mortality at 6 and 24 hours [Срок оценки: 24 hours]
• Death from haemorrhage at 6 and 24 hours [Срок оценки: 24 hours]
• Ventilator free days up to day 28 [Срок оценки: 28 days]
• Symptomatic thromboembolic events to 28 days [Срок оценки: 28 days]
• Quality of life at 3, 6 and 12 months [Срок оценки: 12 Months]
• Health and disability at 3, 6 and 12 months [Срок оценки: 12 months]
• Functional outcome (Patients with TBI) at 12 months [Срок оценки: 12 months]
• Organ failure assessment [Срок оценки: 28 days]

Критерии участия

Критерии включения

• Adult affected by trauma (≥18yrs)
• Judged to have active haemorrhage by treating clinician
• Activation of local MHP and/or Transfusion of Emergency Blood Products
• FIBTEM A5 ≤ 10mm or TEG FF A5 ≤ 15mm or FibC ≤ 2 g/l

Критерии исключения

• Injury judged incompatible with survival
• Randomisation unable to occur within 6 hours of presentation to hospital
• Known pregnancy
• Known genetic or drug induced coagulation disorder
• Known objection to blood products
• Dedicated prior fibrinogen replacement
• Participation in a competing study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

Австралия · 20 центров

• John Hunter Hospital — Newcastle
• St Vincent's Hospital — Sydney
• Royal Prince Alfred Hospital — Sydney
• Royal North Shore Hospital — Sydney
• Westmead Hospital — Sydney
• Liverpool Hospital — Sydney
• Royal Darwin Hospital — Darwin
• Royal Brisbane and Women's Hospital — Brisbane
• … и ещё 12 центров

Новая Зеландия · 4 центра

• Aukland City Hospital — Auckland
• Middlemore Hospital — Auckland
• Waikato Hospital — Hamilton
• Wellington Hospital — Wellington

Публикации

• Fatovich DM, Carey S, Iliff J, Jowitt T, Weber DG, Vance JS. Integrating Research Practice Into Resuscitation Simulation Training Improves Recruitment Into Complex Clinical Trials. Emerg Med Australas. 2025 Jun;37(3):e70064. doi: 10.1111/1742-6723.70064. PMID 40420619

Идентификаторы

NCT: NCT05449834 · ANZIC-RC/ZM001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗